skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Uses of monoclonial antibody 8H9

Abstract

This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light chain CDR3 comprises QNGHSFPLT. In another embodiment, there is provided a polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the polypeptide comprises NYDIN, WIFPGDGSTQY, QTTATWFAY, RASQSISDYLH, YASQSIS, and QNGHSFPLT.

Inventors:
Issue Date:
Research Org.:
Sloan-Kettering Inst. for Cancer Research, New York, NY (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1185299
Patent Number(s):
9062110
Application Number:
13/858,234
Assignee:
Sloan-Kettering Institute for Cancer Research (New York, NY)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A01 - AGRICULTURE A01K - ANIMAL HUSBANDRY
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
DOE Contract Number:  
FG02-93ER61658
Resource Type:
Patent
Resource Relation:
Patent File Date: 2013 Apr 08
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Cheung, Nai-Kong V. Uses of monoclonial antibody 8H9. United States: N. p., 2015. Web.
Cheung, Nai-Kong V. Uses of monoclonial antibody 8H9. United States.
Cheung, Nai-Kong V. Tue . "Uses of monoclonial antibody 8H9". United States. https://www.osti.gov/servlets/purl/1185299.
@article{osti_1185299,
title = {Uses of monoclonial antibody 8H9},
author = {Cheung, Nai-Kong V.},
abstractNote = {This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light chain CDR3 comprises QNGHSFPLT. In another embodiment, there is provided a polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the polypeptide comprises NYDIN, WIFPGDGSTQY, QTTATWFAY, RASQSISDYLH, YASQSIS, and QNGHSFPLT.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2015},
month = {6}
}

Patent:

Save / Share:

Works referenced in this record:

Detection of (11; 22)(q24;q12) Translocation-Bearing Cells in Peripheral Blood Progenitor Cells of Patients With Ewing's Sarcoma Family of Tumors
journal, March 1995


T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients
journal, February 1996


In vivo tracking of tumor-specific T cells
journal, April 2001


Surface Antigen Expression and Complement Susceptibility of Differentiated Neuroblastoma Clones
journal, March 2000


SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
journal, January 1994


Expression of 300-kilodalton intermediate filament-associated protein distinguishes human glioma cells from normal astrocytes.
journal, September 1993


Intra-abdominal desmoplastic small cell tumor: A light microscopic, immunocytochemical, ultrastructural, and flow cytometric study
journal, August 1993


New monoclonal antibodies specific for human sarcomas
journal, July 1986


The Diagnostic Utility of Desmin: A Study of 584 Cases and Review of the Literature
journal, March 1990


Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas
journal, November 1993


Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients
journal, January 1995


Diagnostic imaging of human neuroblastoma with radiolabeled antibody.
journal, November 1986


A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2
journal, May 1991


High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors
journal, December 1997


Immunocytokines: A Promising Approach to Cancer Immunotherapy
journal, December 1998


Functional expression of chimeric receptor genes in human T cells
journal, February 2001


Role of High-Dose Chemotherapy With Hematopoietic Stem Cell Rescue in the Treatment of Metastatic or Recurrent Rhabdomyosarcoma
journal, January 2001


Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.
journal, March 1994


Phage Library-derived Human Anti-TETA and Anti-DOTA ScFv for Pretargeting RIT
journal, February 1999


Monoclonal antibody against ependymoma-derived cell line
journal, January 1992


A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a
journal, May 1992


Intergroup Rhabdomyosarcoma Study: Update for Pathologists
journal, November 1998


Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
journal, November 1979


Human Glioma-Specific Antigens Detected by Monoclonal Antibodies
journal, January 1992


Continuous cultures of fused cells secreting antibody of predefined specificity
journal, August 1975


Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy
journal, July 1997


Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immmunotherapy
journal, June 1997


Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing’s sarcoma
journal, November 1998


A Monte Carlo approach to patient-specific dosimetry
journal, September 1996


Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene
journal, August 1994


Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
journal, January 1993


Biotechnological and gene therapeutic strategies in cancer treatment
journal, June 1995


Clinical Applications of CD34 + Peripheral Blood Progenitor Cells (PBPC)
journal, March 2000


Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes
journal, August 1998


Impact of chimeric immune receptor extracellular protein domains on T cell function
journal, March 1999


Autologous stem cell transplantation for high-risk pediatric solid tumors
journal, September 1999


Efficient Discrimination between Different Densities of Target Antigen by Tetracycline-Regulatable T Bodies
journal, March 1999


Superantigen-staphylococal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells
journal, March 1995


Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial
journal, February 1996


Radionuclide photon dose kernels for internal emitter dosimetry
journal, May 1996


Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
journal, April 1988


Myogenin is a Specific Marker for Rhabdomyosarcoma: An Immunohistochemical Study in Paraffin-Embedded Tissues
journal, September 2000


Title>Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells
journal, November 1997


Detection of Prostatic Specific Membrane Antigen Messenger RNA Using Immunobead Reverse Transcriptase Polymerase Chain Reaction
journal, January 1999


A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
journal, January 1995


The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour
journal, November 1997


The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y
journal, June 1991


Multimodality Diagnostics and Megatherapy in Poor Prognosis Ewing's Tumor Patients
journal, October 1999


Common Musculoskeletal Tumors of Childhood and Adolescence
journal, July 1999


Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours
journal, August 1999


Radiotherapy and High-Dose Chemotherapy in Advanced Ewing's Tumors
journal, October 1999


Radioimmunotherapy with alpha-emitting nuclides
journal, September 1998


Disialoganglioside GD2 anti-idiotypic monoclonal antibodies
journal, May 1993


Expression of CD44 splice variants in human primary brain tumors
journal, December 1995